VSY Biotech develops new treatment for osteoarthritis

By Jeyhun Aliyev

ANKARA (AA) - VSY Biotechnology has developed an innovative new treatment for osteoarthritis that improves patients’ life quality without the need for surgery, the Dutch-based company announced on Tuesday.

The new solution, recently accepted worldwide, uses sodium hyaluronate intra-articular injections to slow the progression of osteoarthritis, a VSY statement said.

"The treatments’ aim is to improve the quality of life in the long term without joint replacement surgery," it added.

The knee, hip, ankle, finger, and spinal joints are among the bodily sites most commonly affected caused by osteoarthritis, including the accompanying aches and pains.

VSY Biotechnology also noted how osteoarthritis affects patients' daily life, making it hard to walk, climb stairs, or stand for extended periods.

"Measures and current treatment methods can slow the progression of osteoarthritis, which is more common in people over 40 years old," said the statement.

The new intra-articular injections also aim to hold back the last stage of the disease, which can require prosthetic surgery.

Only a few companies in the world -- one of which is VSY Biotechnology -- are able to produce the sodium hyaluronate intra-articular injections, said the company.

"As a result of long studies, the Reviscon-branded intra-articulatory injection line with international quality standards was developed by their research and development center," it added.

Dutch-based VSY Biotechnology’s product range includes intraocular lenses, viscoelastics, and injector and cartridge systems.